SMAD7 and colitis: Blockade of SMAD7 activity with an anti-sense oligonucleotide enhanced SMAD2 activation and reduced inflammatory cytokine production in intestinal explants (128) and severity of colitis in mice sensitized and treated with TNBS or oxazolone (29).